Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated ...

Specifically, the PASI-75 response rate was 31.4% for the 25-mg twice-daily dose cohort, 74.3% for those receiving a 50-mg dose twice a day and and 59.5% for the 100-mg daily dose group, compared ...

Provided by PR NewswireMay 29, 2025, 11:01:00 AM Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 ...

JAK1 signaling promotes skin inflammation and is a major therapeutic target for atopic dermatitis-related itching. But in a study appearing in the Jan. 4, 2024, print issue of Cell after earlier ...

The JAK1 inhibitor LNK01001 significantly improved eczema area and severity at 12 weeks of treatment, according to Lynk's Aug. 9 release.

The JAK1 inhibitor was given for six weeks in 21 patients with advanced non-small cell lung cancer (NSCLC), but only after they had received two doses of anti-PD1 immunotherapy.

Source Reference: Song Y, et al "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm ...